Description: Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops precision oncology medicines. The company's lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1/2 for use in the treatment of platinum-resistant ovarian cancer; endometrial and bladder cancer; and SCCs, including SCCHN, cervical, and anal cancer. It is also developing two preclinical drug programs used to predict tumor sensitivity based on custom OncoSignature tests. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Home Page: www.acrivon.com
ACRV Technical Analysis
480 Arsenal Way
Watertown,
MA
02472
United States
Phone:
617 207 8979
Officers
| Name | Title |
|---|---|
| Dr. Peter Blume-Jensen M.D., Ph.D. | Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer |
| Ms. Kristina Masson M.B.A., Ph.D. | Co-Founder, Executive VP of Business Operations, Site Head, Treasurer, Secretary & Director |
| Ms. Mary-Alice Miller J.D. | Chief Legal Officer |
| Mr. Rasmus Holm-Jorgensen | Chief Financial Officer |
| Dr. Eric J. Devroe Ph.D. | Chief Operating Officer |
| Ms. Katharine Peterson CPA | Vice President of Finance & Accounting |
| Dr. Adam D. Levy M.B.A., Ph.D. | Senior VP and Head of Investor Relations & Corporate Affairs |
| Mr. Bruce Close | Vice President of Quality & Compliance |
| Ms. Parvin Miah | VP & Head of Human Resources |
| Dr. Erick Gamelin M.D., Ph.D. | Chief Development Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.1101 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-11-15 |
| Fiscal Year End: | December |
| Full Time Employees: | 58 |